2,246 Shares in AbbVie Inc. $ABBV Bought by Sheets Smith Investment Management

Sheets Smith Investment Management bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,246 shares of the company’s stock, valued at approximately $520,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. New Capital Management LP boosted its position in shares of AbbVie by 5.9% during the 3rd quarter. New Capital Management LP now owns 3,254 shares of the company’s stock valued at $753,000 after acquiring an additional 180 shares during the last quarter. Talbot Financial LLC raised its stake in AbbVie by 3.9% in the third quarter. Talbot Financial LLC now owns 120,884 shares of the company’s stock valued at $27,989,000 after purchasing an additional 4,537 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in AbbVie by 184.6% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 14,249 shares of the company’s stock valued at $3,299,000 after purchasing an additional 9,242 shares during the last quarter. Rise Advisors LLC grew its stake in AbbVie by 3.4% in the 3rd quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock worth $336,000 after buying an additional 48 shares in the last quarter. Finally, Osprey Private Wealth LLC increased its holdings in shares of AbbVie by 28.6% in the 3rd quarter. Osprey Private Wealth LLC now owns 50,310 shares of the company’s stock worth $11,649,000 after buying an additional 11,200 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $227.44 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The company has a 50-day moving average price of $226.63 and a 200-day moving average price of $210.98. The company has a market cap of $401.98 billion, a price-to-earnings ratio of 172.30, a price-to-earnings-growth ratio of 1.27 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is 496.97%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Morgan Stanley upped their price objective on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Citigroup reduced their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Finally, Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.